Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 6/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL489909 | 0.86 | PKM (0.61) | TRIM24PKMALDH1A1GAALMNA | |
| SCHEMBL29290375 | 0.81 | ATAD2 (0.48) | TRIM24CYP11B1CYP11B2CYP1A2ALDH1A1 | |
| SCHEMBL8556509 | 0.81 | ATAD2 (0.61) | BRD4CYP11B1CYP11B2CYP1A2ALDH1A1 | |
| SCHEMBL29913714 | 0.78 | TMEM97 (0.46) | TRIM24BRD4CREBBPCYP11B1CYP11B2 | |
| SCHEMBL28921765 | 0.78 | TMEM97 (0.46) | TRIM24BRD4CREBBPCYP11B1CYP11B2 | |
| SCHEMBL3200431 | 0.78 | POLB (0.43) | PKMCYP1A2ALDH1A1GAAPOLB | |
| SCHEMBL38660212 | 0.78 | POLB (0.43) | PKMCYP1A2ALDH1A1GAAPOLB | |
| SCHEMBL31249742 | 0.77 | TRIM24 (0.46) | TRIM24BRD4CREBBPPKMCYP11B1 | |
| SCHEMBL19224682 | 0.77 | TRIM24 (0.46) | TRIM24BRD4CREBBPPKMCYP11B1 | |
| SCHEMBL11255201 | 0.77 | SRD5A1 (0.59) | BRD4CREBBPCYP11B1CYP11B2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314125-B2 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-20 | — | — | US | disclosed |
| US-20100204255-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-12 | — | — | US | disclosed |
| US-7745629-B2 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-29 | — | — | US | disclosed |
| US-20080119453-A1 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-22 | — | — | US | disclosed |
| WO-1998007742-A1 | SULFONAMIDES | ZENECA LIMITED (GB) | 1998-02-26 | — | — | WO | disclosed |
| US-5484805-A | LIPOXYGENASE INHIBITORS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1996-01-16 | — | — | US | disclosed |
| EP-0462812-B1 | Pyran derivatives as inhibitors of 5-lipoxygenase | ZENECA LTD (GB) | 1995-12-06 | — | — | EP | disclosed |
| EP-0466452-B1 | Thioxo heterocycles and their pharmaceutical use | ZENECA LTD (GB) | 1995-09-20 | — | — | EP | disclosed |
| US-5359063-A | Lipoxygenase inhibitor | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-10-25 | — | — | US | disclosed |
| US-5240941-A | Enzyme inhibitors; antiinflammatory agents, antiallergens | ICI PHARMA (FR) | 1993-08-31 | — | — | US | disclosed |
| US-5217978-A | Lipoxygenase inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-06-08 | — | — | US | disclosed |
| EP-0485111-A2 | The use of lipoxygenase and cyclooxygenase inhibitors as synergistic agents | ZENECA LIMITED (GB) | 1992-05-13 | — | — | EP | disclosed |
| EP-0466452-A2 | Thioxo heterocycles and their pharmaceutical use | ZENECA LIMITED (GB) | 1992-01-15 | — | — | EP | disclosed |
| EP-0462812-A2 | Pyran derivatives as inhibitors of 5-lipoxygenase | ZENECA LIMITED (GB) | 1991-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119453-A1 | Bicyclic derivatives as modulators of ion channels | KCNJ2, TRPV1, KCNN3 | TRIM24 4526/4885BRD4 485/4885CREBBP 2698/4885 |
| US-20100204255-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPV1, KCNN3 | TRIM24 4526/4885BRD4 485/4885CREBBP 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.